Kairos Pharma Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial evaluating ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC). The analysis revealed a statistically significant difference in progression-free survival (PFS), with a median PFS of 17.7 months for patients receiving ENV-105 plus apalutamide compared to two months for those receiving apalutamide alone (P=0.0008). This marked improvement suggests that ENV-105 may reverse resistance to standard therapy, a critical unmet need in prostate cancer treatment.
ENV-105 is an antibody that targets CD105, a protein identified as a key driver of drug resistance and disease relapse. By inhibiting CD105, ENV-105 aims to restore the effectiveness of standard therapies across multiple cancer types. The interim data support this mechanism and provide hope for patients who have become resistant to androgen signaling inhibitors. The company has modified the Phase 2 protocol to enroll patients earlier in disease progression. Patients who experience a PSA increase following upfront treatment with an androgen signaling inhibitor will be randomized to receive either enzalutamide alone or enzalutamide in combination with ENV-105. This change is intended to expand the eligible patient population and facilitate enrollment. Completion of the Phase 2 trial is targeted for the fourth quarter of 2027 or earlier.
For investors and industry observers, the interim results are a significant milestone for Kairos Pharma, a Los Angeles-based oncology therapeutics company utilizing structural biology to overcome drug resistance and immune suppression. The statistically significant PFS benefit could position ENV-105 as a promising addition to the treatment landscape for mCRPC, a condition with limited options once resistance develops. If subsequent trial phases confirm these findings, ENV-105 could become a key component of combination regimens, potentially extending survival and improving quality of life for patients. The broader implications for the pharmaceutical industry include validation of CD105 as a therapeutic target and encouragement for further research into antibody-based strategies to combat drug resistance.
The full press release is available at https://ibn.fm/EDpxx. The latest news and updates relating to Kairos Pharma are available in the company's newsroom at https://ibn.fm/KAPA. For more information about Kairos Pharma, visit Kairos Pharma (NYSE American: KAPA).
This news was distributed through BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. The platform offers editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution to millions of followers. For a full array of tailored corporate communications solutions, visit IBN's website. Full terms of use and disclaimers are available at https://www.BioMedWire.com/Disclaimer.
